SEC Form 4 · accession 0001865125-26-000004
Enliven Therapeutics, Inc. · ELVN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mika K Derynck
Director
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 8:18 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001672619
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 4, 2026 | M | 87,373 | $2.48 | A | 87,373 | D | |
| Common Stock | Aug 4, 2026 | M | 27,567 | $25.28 | A | 114,940 | D | |
| Common Stock | Aug 4, 2026 | M | 23,364 | $14.85 | A | 138,304 | D | |
| Common Stock | Aug 4, 2026 | M | 20,491 | $22.47 | A | 158,795 | D | |
| Common StockF2 | Aug 4, 2026 | S | 158,795 | $60.2134 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.48 | Aug 4, 2026 | M | 87,373 | D | — | Aug 1, 2031 | Common Stock | 87,373 | 0 | D |
| Stock Option (right to buy)F3 | $25.28 | Aug 4, 2026 | M | 27,567 | D | — | Feb 23, 2033 | Common Stock | 27,567 | 0 | D |
| Stock Option (right to buy)F3 | $14.85 | Aug 4, 2026 | M | 23,364 | D | — | Feb 13, 2034 | Common Stock | 23,364 | 0 | D |
| Stock Option (right to buy)F3 | $22.47 | Aug 4, 2026 | M | 20,491 | D | — | Feb 6, 2035 | Common Stock | 20,491 | 0 | D |
Explanation of responses
- F1The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 8, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $60.00 to $60.58. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- F3All of the shares subject to this option are fully vested and exercisable as of the date hereof.